Comparative Pharmacology
Head-to-head clinical analysis: PIPERACILLIN TAZOBACTAM versus PROBAMPACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERACILLIN TAZOBACTAM versus PROBAMPACIN.
Piperacillin-Tazobactam vs PROBAMPACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
100 mg IV every 12 hours over 30 minutes.
None Documented
None Documented
Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD).
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category A/B
Category C
Penicillin Antibiotic + Beta-Lactamase Inhibitor
Penicillin Antibiotic